Connor, Clark & Lunn Investment Management (CC&L)
ATNM icon

Connor, Clark & Lunn Investment Management (CC&L)’s Actinium Pharmaceuticals ATNM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,563
Closed -$90K – 981
2020
Q4 		$90K Buy
+11,563
New +$126K ﹤0.01% 859

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ATNM Position: Q1 2021 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Actinium Pharmaceuticals (ATNM) in Q1 2021, closing a stake of 11,563 shares — an estimated $90K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ATNM in Q4 2020 and held it in 1 quarter. The position peaked at $90K in Q4 2020. 40 funds tracked by Wall St. Rank hold ATNM as of Q1 2021.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Actinium Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 11,563 Actinium Pharmaceuticals shares in Q1 2021, an estimated $90K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Actinium Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Actinium Pharmaceuticals position peaked at $90K in Q4 2020.
  • 40 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2021.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2021, filed 13 May 2021.